Ozempic vs. Saxenda

See how Ozempic and Saxenda compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Ozempic is FDA-approved for type 2 diabetes and to lower cardiovascular and kidney risk; using it for weight loss is off-label, while Saxenda is FDA-approved specifically for chronic weight management.

  • Ozempic is injected once a week, but Saxenda requires a daily injection with a longer titration schedule.

  • Saxenda causes gastrointestinal side effects more often, with nausea reported in about 39% of users compared to up to 20% for Ozempic.

Ozempic vs. Saxenda Drug Summary

Ozempic

Ozempic is a GLP-1 receptor agonist FDA-approved to control blood sugar in type 2 diabetes and to lower cardiovascular and kidney risk in adults with heart or kidney disease. It's injected once a week, with the dose slowly raised from 0.25 mg up to 2 mg. Some people use it off-label for weight loss, since it shares its active ingredient with Wegovy.

Saxenda

Saxenda is a GLP-1 receptor agonist FDA-approved for chronic weight management in adults and adolescents 12 and older with obesity or a weight-related condition. It's injected once a day, with the dose raised weekly from 0.6 mg up to a 3 mg maintenance dose. It shares its active ingredient, liraglutide, with Victoza, which is approved for diabetes instead.

Ozempic vs. Saxenda Side Effects

Ozempic

Most common
nausea (up to 20.3%)
vomiting (up to 9.2%)
diarrhea (up to 8.8%)
constipation (up to 5.0%)

Saxenda

Most common
nausea (up to 39.3%)
vomiting (up to 15.7%)
diarrhea (up to 20.9%)
constipation (up to 19.4%)

Ozempic vs. Saxenda Dosage

Ozempic

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.25 mg once weekly Weeks 1-4
Maximum dose 2 mg once weekly If needed
Dose changes 3 increases Every 4 weeks

Saxenda

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.6 mg once daily Week 1
Maximum dose 3 mg once daily Week 5 onward
Dose changes 4 increases Every week

Ozempic vs. Saxenda Indications

Ozempic

Ozempic is approved to improve blood sugar control in adults with type 2 diabetes, along with diet and exercise. It also carries approvals to reduce cardiovascular risk in diabetics with known heart disease and to slow kidney disease progression in diabetics with chronic kidney disease. It is not approved for weight loss on its own.

  • Blood sugar control in type 2 diabetes, with diet and exercise

  • Reduce risk of heart attack, stroke, and death in T2D with heart disease

  • Slow kidney disease progression in T2D with chronic kidney disease

  • Not approved for chronic weight management (that's Wegovy)

Saxenda

Saxenda is approved for chronic weight management in adults with obesity, or overweight with a related condition like high blood pressure. It's also approved for adolescents ages 12 to 17 with obesity. It is not approved to treat type 2 diabetes; that use belongs to Victoza, a different liraglutide product.

  • Chronic weight management in adults with obesity

  • Chronic weight management in overweight adults with a related condition

  • Chronic weight management in adolescents 12-17 with obesity

  • Not approved for type 2 diabetes (see Victoza)

Ozempic vs. Saxenda Pros and Cons

Ozempic

Ozempic's once-weekly dosing and added cardiovascular and kidney benefits make it a strong option for people with type 2 diabetes. Since it isn't FDA-approved for weight loss, insurance coverage for that use is inconsistent and often requires paying out of pocket.

Pros

  • Only needs to be injected once a week, not daily

  • FDA-approved to reduce cardiovascular risk in T2D with heart disease

  • FDA-approved to slow kidney disease progression in T2D with CKD

  • Longer real-world track record in type 2 diabetes since 2017

Cons

  • Not FDA-approved for weight loss, so that use is off-label

  • No pediatric weight-loss approval

  • Insurance often won't cover it for weight management alone

Saxenda

Saxenda is FDA-approved specifically for chronic weight management, giving it more consistent insurance coverage for that use than off-label options. It requires a daily injection and tends to cause gastrointestinal side effects more often than once-weekly GLP-1 drugs.

Pros

  • FDA-approved specifically for chronic weight management

  • Approved for adolescents 12-17 with obesity

  • More consistent insurance coverage for weight-loss use

  • Established weight-loss track record since 2014

Cons

  • Requires a daily injection instead of once a week

  • Higher rates of nausea, diarrhea, and vomiting than Ozempic

  • Not approved for type 2 diabetes or cardiovascular/kidney risk reduction

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.